Name:
How could the STAMPEDE trial shape prostate cancer care?
Description:
How could the STAMPEDE trial shape prostate cancer care?
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/fc86f847-5507-4c19-b562-507e1a1a78fc/videoscrubberimages/Scrubber_6.jpg
Duration:
T00H11M18S
Embed URL:
https://stream.cadmore.media/player/fc86f847-5507-4c19-b562-507e1a1a78fc
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/fc86f847-5507-4c19-b562-507e1a1a78fc/Veracyte ESMO22 interview V2 (1).mp4?sv=2019-02-02&sr=c&sig=aTuoJ6m9%2B%2F%2BS3puL5T26EdhxdTgp%2B8bO%2BuhSt575rnc%3D&st=2024-05-14T13%3A05%3A43Z&se=2024-05-14T15%3A10%3A43Z&sp=r
Upload Date:
2022-10-09T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
MARK STAPLEY: Hi, my name is Mark Stapley. I'm CEO of Veracyte, a leading diagnostics company based in San Francisco in the USA. I've been with Veracyte now for just over a year. I've spent the last 10 years in the genomics industry at companies like Illumina, which is a very well-known sequencing company and Helix, which is a population genomics company. Prior to that, I was with Pfizer, so in the pharmaceutical industry.
MARK STAPLEY: And before that, I was in other industries outside of health care.
ELAI DAVICIONI: My name is Elai Davicioni. I started a company called Decipher about 15 years ago, which last year was acquired by Veracyte. I'm a bioinformatician by training.
MARK STAPLEY: The STAMPEDE data that Elai is going to talk about is really important to the Decipher Prostate test. Decipher is a test that, we believe, is actually the most used test in prostate cancer diagnosis and prognosis today, or rather, in prognosis today. It is a test that is under guidelines for many indications, but one additional indication that I think is important for all prostate cancer patients or men with prostate cancer is metastatic and high risk.
MARK STAPLEY: So I'll ask Elai to talk about how this STAMPEDE data really helps that particular patient cohort.
ELAI DAVICIONI: Yes, STAMPEDE is a multi-stage, multi-arm, large, randomized Phase III trial that's mostly conducted in the UK, and it's enrolled over 11,000 prostate cancer patients to date. We've done an analysis so far of one of the STAMPEDE comparisons. It's called Arm G, in which randomized patients to receive standard-of-care hormonal therapy with or without novel hormonal therapy, abiraterone, acetate, and prednisone.
ELAI DAVICIONI: The significance of the STAMPEDE analysis, which will be presented tomorrow at this meeting, is it really shows for the first time the ability of Decipher to accurately restratify patients with metastatic disease. And also, we've shown this before but in much greater detail how we can further restratify even men with very high-risk, localized disease. And why this is important, as men that are diagnosed with these conditions, they face many years of hormonal therapy treatment, and these treatments come with lots of side effects.
ELAI DAVICIONI: What we found in the STAMPEDE analysis is that some men had much greater benefit from getting these powerful drugs than others. And so using this information, in the near future, physicians will be able to order the Decipher for these patients and then better tailor or individualize care for their patients, so which ones should get these additional drugs versus which ones actually will do quite well with standard therapies.
MARK STAPLEY: I think this is really important for those patients because, today, those patients and their physicians that typically don't use a molecular diagnostic, like Decipher Prostate, that looks across the whole transcriptome. In addition to the great data that's being presented, by leveraging the whole transcriptome, we're also able to look at additional data for patients using something that we call Decipher GRID, which enables additional biomarkers to be studied, and we're seeing some interesting results come out of that work as well.
MARK STAPLEY: These patients can be undergoing this treatment for many, many years, as long as 10 years, in particular. And so choosing the appropriate course of treatment and having the most information available to you when you're doing that, for both the physician and the patient, is critically important.
ELAI DAVICIONI: We're really honored and privileged to work with the STAMPEDE consortium. So we're continuing to work on additional arms, looking at additional questions to see whether our test and the information that our test provides can help individualize care for men that are considering other types of therapy for advanced prostate cancer. And then, also, in this study, we're further doing additional analysis to better understand some of the other biomarkers that we capture with our assay besides the Decipher test.
ELAI DAVICIONI:
MARK STAPLEY: Veracyte is working very hard to bring the diagnostic test that we have used our robust science to create to patients all over the world. We have some of the leading tests on the market today. So we've talked a little bit about Decipher Prostate. We also have the leading thyroid test-- we believe is the leading thyroid test that is available in the United States. Here in Europe, we've already launched as an IVD for a number of years our Prosigna Breast Cancer test.
MARK STAPLEY: And as I think about the pipeline of tests that we've got ahead of us, we've got other additional tests in urology, like bladder cancer, but what I'm really excited about is our lung portfolio, particularly, on nasal swab test. And maybe, if I could just spend a minute on that, our nasal swab test is a test that can be used for patients who have been identified with a lung nodule.
MARK STAPLEY: And by a simple nasal swab, we're able to classify those patients as low, intermediate, or high risk for lung cancer, which is really important because, firstly, there are millions of people a year around the world who are identified with a lung nodule. In most cases, it is benign, thankfully, but in many cases, it isn't. And in fact, lung cancer is the leading cause of death amongst all the cancers, more than the next top three combined, so really important to be able to accurately stratify those patients and enable those that are low risk to avoid unnecessary procedures but also to enable those that are higher risk to go to an accelerated treatment path.
MARK STAPLEY: Yeah, Prosigna is, we believe, one of the most important tests for breast cancer. It is, as I mentioned, on the European market, has been for a number of years and is reimbursed and utilized in countries like UK, France, Germany, Sweden, Italy. And it is a great test-- and maybe you want to spend a few minutes on that.
MARK STAPLEY: But it's a great test for helping certain patients with the appropriate indication and their physicians-- again, similar to what we've talked about already, prognosis, for risk of recurrence and risk of distant metastasis, and to help guide treatment decisions with the subtypes information that is available in the European market.
ELAI DAVICIONI: Prosigna, I think, certainly, first, accurately stratifying patients and assessing risk, and then secondarily, helping physicians to determine if basically a hormonal therapy approach for women is the best or a nonhormonal therapy approach is the best. And then, also, combination therapies, and there's actually quite a lot of ongoing research to further individualize care for women as well with this test.
MARK STAPLEY: Maybe just one thing, Prosigna is very important for our company as it's the first test that we have in Europe that reinforces the strategy that we're developing as a company. So we have rights to a diagnostic platform. It's called the nCounter. We have the global rights to that. That is the platform that's used by labs locally, closer to the patient, to run the Prosigna test.
MARK STAPLEY: We're in the process of developing and launching a multitude of other tests on that platform. Next year, we're going to be submitting to the regulatory authorities for approval our test for interstitial lung disease, which is a terrible disease for patients who have respiratory issues resulting from fibrosis, so really important. There's a lot of patients who are suffering from this.
MARK STAPLEY: It's already available in the US, so we'll be launching it once it's approved by the regulatory bodies in Europe. The following year, we're submitting the Decipher Prostate test that we've already talked about. The year after, that we'll be submitting the nasal swab lung cancer test that I've discussed, and we expect to continue submitting more tests year after year, so truly enabling our patients outside the US and Europe and beyond to have access to the multitude of tests of various sites developing in our labs around the world.
MARK STAPLEY: In general, we're very excited to be here in general to talk about the great work that Veracyte is doing. We've brought together three companies over the last year, and so now you can see the breadth of portfolio that we have as a company. But what's really unique about the strategy is this idea of launching these tests in the US in a centralized lab mode and then being able to make them available to labs all around the world.
MARK STAPLEY: That isn't something that many other labs are able to do. So we're excited to be able to talk to our customers and KOLs here at ESMO and share the work that we've already done and that we're going to be doing in the future. Elai.
ELAI DAVICIONI: Yeah, I think, also, we have a number of posters at this meeting, and it shows, really, what we can do to individualize care for prostate cancer patients, from very low risk of dying of their disease to very high risk, and also shows how we've been able to work with biopharmaceutical companies also to help them with their products as far as doing biomarker analysis.
MARK STAPLEY: And we've already made a difference in the lives of hundreds of thousands of patients with these tests, and that's really why we exist as a company, is to do exactly that. So looking forward to continuing on that journey.